CN1285588C - 法尼基蛋白转移酶抑制剂 - Google Patents

法尼基蛋白转移酶抑制剂 Download PDF

Info

Publication number
CN1285588C
CN1285588C CNB998162078A CN99816207A CN1285588C CN 1285588 C CN1285588 C CN 1285588C CN B998162078 A CNB998162078 A CN B998162078A CN 99816207 A CN99816207 A CN 99816207A CN 1285588 C CN1285588 C CN 1285588C
Authority
CN
China
Prior art keywords
title compound
compound
dichloromethane
stirred
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998162078A
Other languages
English (en)
Chinese (zh)
Other versions
CN1352642A (zh
Inventor
T·吉兹
D·F·拉内
A·K·马拉姆斯
A·B·库珀
R·J·多尔
V·M·吉里杰瓦尔拉汉
A·G·塔维拉斯
C·斯特里克兰德
J·M·凯利
J·赵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1352642A publication Critical patent/CN1352642A/zh
Application granted granted Critical
Publication of CN1285588C publication Critical patent/CN1285588C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB998162078A 1998-12-18 1999-12-16 法尼基蛋白转移酶抑制剂 Expired - Fee Related CN1285588C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21656098A 1998-12-18 1998-12-18
US09/216,560 1998-12-18

Publications (2)

Publication Number Publication Date
CN1352642A CN1352642A (zh) 2002-06-05
CN1285588C true CN1285588C (zh) 2006-11-22

Family

ID=22807539

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998162078A Expired - Fee Related CN1285588C (zh) 1998-12-18 1999-12-16 法尼基蛋白转移酶抑制剂

Country Status (23)

Country Link
EP (1) EP1140904B1 (enExample)
JP (1) JP2002533335A (enExample)
KR (1) KR20010081115A (enExample)
CN (1) CN1285588C (enExample)
AR (1) AR021716A1 (enExample)
AT (1) ATE293622T1 (enExample)
AU (1) AU2347900A (enExample)
BR (1) BR9916328A (enExample)
CA (1) CA2354774C (enExample)
CO (1) CO5160344A1 (enExample)
CZ (1) CZ20011900A3 (enExample)
DE (1) DE69924876T2 (enExample)
ES (1) ES2237963T3 (enExample)
HU (1) HUP0203054A3 (enExample)
ID (1) ID29065A (enExample)
IL (1) IL143409A0 (enExample)
NO (1) NO20012960L (enExample)
PE (1) PE20001516A1 (enExample)
PL (1) PL348294A1 (enExample)
SK (1) SK7582001A3 (enExample)
TR (1) TR200101754T2 (enExample)
WO (1) WO2000037458A1 (enExample)
ZA (1) ZA200104236B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2155001A (en) * 1999-11-10 2001-06-06 Aventis Pharma Deutschland Gmbh N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa
US7361663B2 (en) 1999-11-10 2008-04-22 Aventis Pharmaceuticals Inc. N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
US6809093B2 (en) 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
DE60208157T2 (de) 2001-02-16 2006-08-10 Aventis Pharmaceuticals Inc. Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
WO2004060488A1 (en) * 2002-12-17 2004-07-22 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CA2590979A1 (en) 2004-12-13 2006-06-22 Schering Corporation Novel farnesyl protein transferase inhibitors and their use to treat cancer
JP2008523148A (ja) * 2004-12-14 2008-07-03 シェーリング コーポレイション ファルネシルプロテイントランスフェラーゼインヒビターおよび増殖性疾患を処置するための方法
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
CA2724648A1 (en) * 2008-05-22 2009-11-26 Merck Sharp & Dohme Corp. Process for the preparation of an orexin receptor antagonist
HU231150B1 (hu) 2017-03-13 2021-03-29 Richter Gedeon Nyrt Eljárás racém 3-alkilpiperidin-3-karbonsav-etil-észterek optikai izomerjeinek elválasztására
CA3140170A1 (en) 2019-06-04 2020-12-10 Belew Mekonnen Imidazolo derivatives, compositions and methods as orexin antagonists
WO2022029666A1 (en) 2020-08-05 2022-02-10 Richter Gedeon Nyrt. PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种（R）-1-Boc-3-羟甲基哌嗪的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
GB9420172D0 (en) * 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
ZA985203B (en) * 1997-06-17 1999-01-05 Schering Corp Compounds useful for inhibition of farnesyl protein transferase

Also Published As

Publication number Publication date
DE69924876T2 (de) 2006-03-02
PL348294A1 (en) 2002-05-20
ATE293622T1 (de) 2005-05-15
TR200101754T2 (tr) 2002-05-21
EP1140904B1 (en) 2005-04-20
ZA200104236B (en) 2002-08-23
CA2354774A1 (en) 2000-06-29
NO20012960L (no) 2001-08-15
CZ20011900A3 (cs) 2002-02-13
DE69924876D1 (de) 2005-05-25
NO20012960D0 (no) 2001-06-15
CN1352642A (zh) 2002-06-05
AU2347900A (en) 2000-07-12
HUP0203054A2 (hu) 2003-01-28
AR021716A1 (es) 2002-07-31
HUP0203054A3 (en) 2004-01-28
KR20010081115A (ko) 2001-08-27
BR9916328A (pt) 2001-10-02
IL143409A0 (en) 2002-04-21
PE20001516A1 (es) 2001-01-06
CO5160344A1 (es) 2002-05-30
ES2237963T3 (es) 2005-08-01
ID29065A (id) 2001-07-26
WO2000037458A1 (en) 2000-06-29
CA2354774C (en) 2009-05-26
EP1140904A1 (en) 2001-10-10
HK1036279A1 (en) 2001-12-28
SK7582001A3 (en) 2002-03-05
JP2002533335A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
CN1285588C (zh) 法尼基蛋白转移酶抑制剂
CN1100777C (zh) 作为nos抑制剂的n－杂环衍生物
CN1213040C (zh) 丝氨酸蛋白酶抑制剂
CN1052224C (zh) 哌啶衍生物、含有它的外周血管舒张剂及其应用
CN1174978C (zh) 用作旋转异构酶抑制剂的杂环化合物
CN1103770C (zh) 喹喔啉二酮化合物
CN1390201A (zh) 作为ccr5拮抗剂的环胺化合物
CN1538969A (zh) 新颖苯并噻吩基或吲哚衍生物,其制备和其作为蛋白质异戊烯转移酶抑制剂的用途
CN1195340A (zh) 法呢基蛋白转移酶抑制剂
CN1084849A (zh) 双重作用抑制剂
CN1173132A (zh) 二氢嘧啶类化合物及其用途
CN1085546A (zh) 胺二醇蛋白酶抑制剂
CN1708493A (zh) 选择的cgrp拮抗剂、其制法及作为药物的用途
CN1253547A (zh) 1,4－取代环胺衍生物
CN1030415A (zh) 饱和的杂环碳酰胺衍生物和它的制备方法
CN1106003A (zh) 微粒体甘油三酯转移蛋白的抑制剂和方法
CN1489580A (zh) 咪唑衍生物
CN1176640A (zh) 微粒体甘油三酯转移蛋白的抑制剂和方法
CN1930143A (zh) 具有微粒体甘油三酸酯传递蛋白质抑制活性的被五元杂环取代的芳基哌啶或哌嗪
CN1154699A (zh) 用作速激肽拮抗剂的(氮杂环丁-1-基烷基)内酰胺
HK1039324A1 (zh) 用作氧化氮合成酶抑制剂的环状脒基制剂
CN1209125A (zh) 作为速激肽拮抗剂的哌嗪类衍生物
CN1993331A (zh) N－(1－(1－苄基－4－苯基－1h－咪唑－2－基 )－2 , 2－二甲基丙基)苯甲酰胺衍生物和相关化合物作为用于治疗癌症的驱动蛋白纺锤蛋白(ksp)抑制剂
CN1040748C (zh) 苯并吖庚因衍生物及其药物组合物和中间体
CN1266431A (zh) 芳基－哌嗪衍生物、及其制备和作为速激肽拮抗剂的应用

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061122

Termination date: 20100118